Search results
Results From The WOW.Com Content Network
It is particularly used for infections of the skin, respiratory system and mammary glands in dogs and cats, as well as with urinary tract infections. For dogs, a dose ranges from 2.75 - 5.5 mg/kg once a day. The duration of treatment is usually at least five days, longer if there is a concurrent fungal or yeast infection. [4]
Oclacitinib, sold under the brand name Apoquel among others, is a veterinary medication used in the control of atopic dermatitis and pruritus from allergic dermatitis in dogs at least 12 months of age. [1] [4] Chemically, it is a synthetic cyclohexylamino pyrrolopyrimidine janus kinase inhibitor that is relatively selective for JAK1. [5]
DMA, also known as 1-dehydrochlormadinone acetate, as well as 1,6-didehydro-6-chloro-17α-acetoxyprogesterone or '6-chloro-17α-hydroxypregna-1,4,6-triene-3,20-dione, is a synthetic pregnane steroid and a derivative of progesterone.
The minimum lethal dose in dogs is over 5 mg/m 2; dogs have tolerated getting ten times the standard dose. [9] [33] Signs of overdose include panting, trembling, vomiting, and diarrhea, as well as increased blood levels of creatine kinase, aspartate transaminase, and alanine transaminase. Dogs who received atipamezole without first receiving ...
The approximate calculation for canine efficacy dose is between the range of 1.3 and 1.7 mg/kg, in conjunction with a methylcellulose suspending agent. Based on the calculations from the comparisons of binding affinity of grapiprant to the EP4 receptors of dogs, rats, and humans, the study of plasma and serum protein binding determinations, the ...
Dogs receiving 10 times the labeled dosage rate of enrofloxacin for at least 14 days developed only vomiting and anorexia. Death did occur in some dogs when fed 25 times the labeled rate for 11 days, however. Oral LD 50: greater than 5000 mg/kg; Dermal LD 50: greater than 2000 mg/kg; Inhalation LD 50: greater than 3547 mg/m3 (4-hour exposure)
Maropitant (INN; [3] brand name: Cerenia, used as maropitant citrate , is a neurokinin-1 (NK 1) receptor antagonist developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007, for use in dogs [4] [5] and in 2012, for cats. [6]
It is the first medication developed specifically for the treatment of cancer in dogs. [4] [5] It is used as its phosphate salt, toceranib phosphate. It was developed by SUGEN as SU11654, [6] a sister compound to sunitinib, which was later approved for human therapies. Toceranib is a tyrosine kinase inhibitor and works in two ways: by killing ...